Dimerix Limited (ASX:DXB) | Dimerix Expands Pipeline with Acquisition of Phase 2 Asset

Episode Summary: Dimerix Limited (ASX:DXB) Acquires Phase 2 Ready Acute Kidney Injury Asset DMX 652 This episode explores Dimerix's acquisition of DMX 652, a Phase 2 ready drug candidate targeting acute kidney injury, expanding the company's renal pipeline alongside its Phase 3 DMX 200 program. We cover the acquisition terms, planned Phase 2 clinical trial, funding position and the key milestones outlined in the ASX announcement.